GENUS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,718 GBX | -2.16% |
|
-4.13% | -20.83% |
| Apr. 17 | Gigantic marine reptile's fossils found by British girl and father | RE |
| Mar. 08 | Genus Power Infrastructures Forms New Subsidiary | MT |
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.54 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.83% | 1.43B | B | ||
| -1.42% | 41.35B | B | ||
| +42.15% | 40.38B | A | ||
| +1.97% | 39.05B | B- | ||
| -14.19% | 26.67B | C | ||
| +1.82% | 24.07B | B- | ||
| -24.55% | 18.36B | B | ||
| -4.07% | 11.68B | C+ | ||
| +21.36% | 11.6B | C+ | ||
| +8.20% | 11.15B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GNS Stock
- Ratings Genus plc
